Department / Division
Medicine / Medicine - Hematological Malignancies
Durham, NC 27710
Myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN/MPD), chronic myeloid leukemia (CML); other hematologic malignancies such as acute lymphoid leukemia (ALL), non-hodgkin lymphomas (NHL)
Thomas W. LeBlanc, M.D., M.A.
Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy
Investigator, Center for Learning Health Care, Duke Clinical Research Institute
Faculty Associate, Trent Center for Bioethics, Humanities and History of Medicine
Dr. LeBlanc is a medical oncologist and palliative care physician. His practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs). He is an active member of the inpatient non-transplant hematologic malignancies care team, based on the 9100 ward of Duke Hospital.
Dr. LeBlanc's research interests converge on common issues faced by patients with advanced cancers, particularly those with high-risk or relapsed/refractory hematologic malignancies. Issues of symptom burden, quality of life, prognostication and prognostic understanding are of central importance in these settings, and may lead patients to face difficult decision-making scenarios. Dr. LeBlanc’s research explores the experience of patients and families in these settings, and aims towards the development of targeted interventions to improve the experience of patients with blood cancers, including the involvement of specialist palliative care services as part of their comprehensive cancer care.
Dr. LeBlanc is the recipient of a Junior Career Development Award grant from the National Palliative Care Research Center (NPCRC). This grant currently funds his research efforts to better understand the experience of patients with AML, including symptom burden, longitudinal quality of life, and prognostic understanding. This work is mentored by a team of expert researchers at Duke, including Drs. Amy Abernethy, James Tulsky, Karen Steinhauser, and Peter Ubel. Dr. LeBlanc's work thus far led to his recognition as a 2012 "Research Scholar" by the American Academy of Hospice and Palliative Medicine.
Dr. LeBlanc is an appointed member of the Ethics Committee of the American Society of Clinical Oncology, an active member of the American Academy of Hospice and Palliative Medicine, and sits on the Scientific Review Committee of the NIH-funded Palliative Care Research Cooperative Group. He also represents the Duke Cancer Institute, a National Comprehensive Cancer Network (NCCN) member, on the NCCN panel for cancer-related fatigue.
Dr. LeBlanc completed residency training in Internal Medicine at Duke, as well as fellowships in Medical Oncology and Hospice and Palliative Medicine. He graduated from the Duke University School of Medicine, also earning a Master of Arts degree in Philosophy during that time, and served as Chief Medical Resident at the Durham VA Medical Center. He holds board certifications in Internal Medicine, and in Hospice and Palliative Medicine. He is actively involved with teaching of medical students and housestaff at Duke, particularly with regards to issues of patient-doctor communication.
This faculty member has no reported relationships with industry.